{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460024985
| IUPAC_name = (6''R'',7''R'')-7-<nowiki>[[</nowiki>(2''Z'')-2-(5-amino-1,2,4-thiadiazol-3-ylidene)- 2-nitroso-1-oxoethyl]amino]-8-oxo-3-[(''E'')-[2-oxo-1-[(3''R'')- 3-pyrrolidinyl]-3-pyrrolidinylidene]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Ceftobiprole2DCSD.svg
| width = 300px

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|ceftobiprole}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = Marketed in the UK, France, Italy, Germany, Austria, Switzerland
| routes_of_administration = Intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 209467-52-7
| CAS_supplemental = <br/>{{CAS|252188-71-9}} (medocaril)
| ATC_prefix = J01
| ATC_suffix = DI01
| ATC_supplemental = <ref>{{cite web|url=http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL |title=ATC/DDD Classification (FINAL): New ATC 5th level codes |date=August 27, 2008 |author=WHO International Working Group for Drug Statistics Methodology |publisher=WHO Collaborating Centre for Drug Statistics Methodology |accessdate=2008-09-05 |deadurl=yes |archiveurl=https://web.archive.org/web/20080506023243/http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL |archivedate=2008-05-06 |df= }}</ref>
| PubChem = 6918430
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5T97333YZK
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08885
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 520642
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 23350302
<!--Chemical data-->
| C=20 | H=22 | N=8 | O=6 | S=2 
| molecular_weight = 534.568 g/mol
| smiles = C1CNC[C@@H]1N2CC/C(=C\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\O)/c5nc(sn5)N)SC3)C(=O)O)/C2=O
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = VOAZJEPQLGBXGO-SDAWRPRTSA-N
}}

'''Ceftobiprole''' ('''Zevtera'''/'''Mabelio''') is a new 5th-generation<ref>{{Cite journal|last=Scheeren|first=Thomas W. L.|date=2015-01-01|title=Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia|journal=Future Microbiology|volume=10|issue=12|pages=1913–1928|doi=10.2217/fmb.15.115|issn=1746-0921|pmid=26573022}}</ref> [[cephalosporin]]e for the treatment of [[hospital-acquired pneumonia]] (HAP, excluding ventilator-associated pneumonia, VAP) and [[community-acquired pneumonia]] (CAP). It is marketed by [[Basilea Pharmaceutica]] in the United Kingdom, Germany, Switzerland and Austria under the trade name Zevtera, in France and Italy under the trade name Mabelio.<ref>{{cite web | url=http://www.basilea.com/News-and-Media/Basilea-to-launch-Zevtera-Mabelio-ceftobiprole-medocaril-in-Europe-through-a-commercial-services-provider/7dcfb10b-c4ef-5a82-8359-f88b1f36cb96/ | title=Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider | publisher=Basilea Pharmaceutica}}</ref> Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls.  Ceftobiprole has high affinity for [[MecA (gene)|PBP2a]] of [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'' (MRSA)]] strains and retains its activity against strains that express divergent mecA gene homologues (mecC or mecALGA251). Ceftobiprole also binds to PBP2b in ''[[Streptococcus pneumoniae]]'' (penicillin-intermediate), to PBP2x in S. pneumoniae (penicillin resistant), and to PBP5 in ''[[Enterococcus faecalis]]''.<ref>{{Cite journal|last=Syed|first=Yahiya Y.|date=2014-09-01|title=Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia|journal=Drugs|volume=74|issue=13|pages=1523–1542|doi=10.1007/s40265-014-0273-x|issn=0012-6667|pmid=25117196}}</ref>

== Microbiology ==
Ceftobiprole has shown in vitro antimicrobial activity against a broad range of Gram-positive and Gram-negative pathogens. Among the Gram-positive pathogens, ceftobiprole has demonstrated good in vitro activity against methicillin-resistant ''Staphylococcus aureus'' (MRSA), [[Staphylococcus aureus|methicillin-susceptible ''Staphylococcus aureus'' (MSSA)]] and coagulase-negative ''staphylococci'', as well as against MRSA strains with reduced susceptibility to linezolid, daptomycin or vancomycin.<ref>{{cite journal | title=Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. |vauthors=Zhanel GG, Lam A, Schweizer F, Thomson K, Walkty A, Rubinstein E, Gin AS, Hoban DJ, Noreddin AM, Karlowsky JA | year=2008 | pmid=18572975 | doi=10.2165/00128071-200809040-00004 | volume=9 | journal=Am J Clin Dermatol | pages=245–54}}</ref> Ceftobiprole has also displayed potent activity against ''Streptococcus pneumoniae'' (including penicillin-sensitive, penicillin-resistant and ceftriaxone-resistant strains) and ''Enterococcus faecalis'', but not against ''[[Enterococcus faecium]]''. For Gram-negative pathogens, ceftobiprole has shown good in vitro activity against ''[[Haemophilus influenzae]]'' (including both ampicillin-susceptible and ampicillin-non-susceptible isolates), Pseudomonas aeruginosa and strains of ''[[Escherichia coli]], [[Klebsiella pneumoniae]] and [[Proteus mirabilis]]'' not producing extended-spectrum β-lactamase ([[Beta-lactamase|ESBL]]). Like all other cephalosporines, ceftobiprole was inactive against ESBL producing strains.<ref>{{Cite journal|last=Farrell|first=David J.|last2=Flamm|first2=Robert K.|last3=Sader|first3=Helio S.|last4=Jones|first4=Ronald N.|date=2014-07-01|title=Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010|journal=Antimicrobial Agents and Chemotherapy|volume=58|issue=7|pages=3882–3888|doi=10.1128/AAC.02465-14|issn=1098-6596|pmc=4068590|pmid=24777091}}</ref>

The efficacy of ceftobiprole has been demonstrated in two large randomized, double-blind, phase 3 clinical trials in patients with HAP and CAP. Ceftobiprole was non-inferior to ceftazidime plus linezolid in the treatment of HAP (excluding VAP) and non-inferior to ceftriaxone with or without linezolid in the treatment of CAP.<ref>{{Cite journal|last=Farrell|first=David J.|last2=Flamm|first2=Robert K.|last3=Sader|first3=Helio S.|last4=Jones|first4=Ronald N.|date=2014-04-01|title=Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types|journal=International Journal of Antimicrobial Agents|volume=43|issue=4|pages=323–327|doi=10.1016/j.ijantimicag.2013.11.005|issn=1872-7913|pmid=24411474}}</ref><ref>{{Cite journal|last=Nicholson|first=Susan C.|last2=Welte|first2=Tobias|last3=File|first3=Thomas M.|last4=Strauss|first4=Richard S.|last5=Michiels|first5=Bart|last6=Kaul|first6=Pratibha|last7=Balis|first7=Dainius|last8=Arbit|first8=Deborah|last9=Amsler|first9=Karen|date=2012-03-01|title=A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation|journal=International Journal of Antimicrobial Agents|volume=39|issue=3|pages=240–246|doi=10.1016/j.ijantimicag.2011.11.005|issn=1872-7913|pmid=22230331}}</ref>

==Pharmacology==

[[File:Zevtera Front UK(6)(1) (30204271666).jpg|thumb|right|120px]]
Ceftobiprole is the active moiety of the prodrug ceftobiprole medocaril and is available for i.v. treatment only. The recommended dose is 500&nbsp;mg as 2-hour infusion every 8 hours. It is mainly excreted renally. Dose adjustment is required for patients with moderate or severe [[Kidney failure|renal impairment]] and for patients with end-stage renal disease, but no dose adjustment is needed by gender, ethnicity or age, in severely obese patients or in patients with [[Liver disease|hepatic impairment]].<ref>{{Cite journal|last=Awad|first=Samir S.|last2=Rodriguez|first2=Alejandro H.|last3=Chuang|first3=Yin-Ching|last4=Marjanek|first4=Zsuszanna|last5=Pareigis|first5=Alex J.|last6=Reis|first6=Gilmar|last7=Scheeren|first7=Thomas W. L.|last8=Sánchez|first8=Alejandro S.|last9=Zhou|first9=Xin|date=2014-07-01|title=A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia|journal=Clinical Infectious Diseases|volume=59|issue=1|pages=51–61|doi=10.1093/cid/ciu219|issn=1537-6591|pmc=4305133|pmid=24723282}}</ref>

==Regulatory approvals==

[[File:Zevtera 1Vial UK(3)(1) (29608654394).jpg|thumb|right|80px| 500 mg powder]]
Ceftobiprole has been approved for the treatment of adult patients with hospital acquired pneumonia (excluding VAP) and community acquired pneumonia in 12 European countries, Canada and Switzerland.<ref>Basilea Medical Ltd. Summary of Product Characteristics: Zevtera 500 mg powder for concentrate for solution for infusion. Medicines and Healthcare Products Regulatory Agency. <nowiki>http://www.mhra.gov.uk/spc</nowiki></ref>

==Synonyms==
*RO0639141-000<ref name="2001Hebeisen">{{cite journal|year=2001|title=In vitro and in vivo properties of Ro63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci|journal=Antimicrob Agents Chemother|volume=45|issue=3|pages=825–36|doi=10.1128/AAC.45.3.825-836.2001|pmc=90381|pmid=11181368|vauthors=Hebeisen P, Heinze-Krauss I, Angehrn P|display-authors=etal}}</ref>
*BAL9141<ref>{{cite journal|vauthors=Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ |year=2002|title=In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci|journal=J Antimicrob Chemother|volume=50|pages=915–932|url=http://jac.oxfordjournals.org/cgi/content/full/50/6/915?ijkey=44287b37747e341869bed979dc42b8250ff5c6ce|doi=10.1093/jac/dkf249|pmid=12461013|issue=6}}</ref>
*Ceftobiprole medocaril

==References==
<references />{{CephalosporinAntiBiotics}}

[[Category:Cephalosporin antibiotics]]
[[Category:Thiadiazoles]]
[[Category:Oximes]]
[[Category:Pyrrolidines]]
[[Category:Pyrrolidones]]